Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity
- 1 March 2019
- journal article
- review article
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 133, 276-294
Abstract
No abstract availableKeywords
Funding Information
- Cancer Institute of New South Wales (12/ECF/2-17)
- University of Sydney
- Cancer Australia
- Cure Cancer Australia Foundation (APP1086449)
- National Health and Medical Research Council (#1060482)
- Senior Principal Research Fellowship (APP1062607)
This publication has 299 references indexed in Scilit:
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- N‐myc downstream regulated gene 1 modulates Wnt‐β‐catenin signalling and pleiotropically suppresses metastasisEMBO Molecular Medicine, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- The role of iron in mitochondrial functionBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503Investigational New Drugs, 2009
- SnapShot: p53 Posttranslational ModificationsCell, 2008
- Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer CellsChemistry & Biology, 2008
- DNA damage checkpoints: from initiation to recovery or adaptationCurrent Opinion in Cell Biology, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylationJournal of Cellular Biochemistry, 2006